The tweet was deleted by the author.
But we saved everything 🙂.
ATOSSA THERAPEUTICS, INC. is intensifying its attention on mammographic breast density (MBD) as a critical factor in breast cancer prevention research.
According to the company, scientific studies have indicated that reductions in breast density may be correlated with a lower risk of developing breast cancer in the future. This association has prompted researchers at ATOSSA THERAPEUTICS, INC. to continue exploring new options, including the potential benefits of low-dose therapies aimed at reducing MBD and mitigating breast cancer risk.
ATOSSA THERAPEUTICS, INC. has pursued research across multiple rare and complex diseases. The company recently received FDA rare pediatric disease designation for (Z)-endoxifen in the treatment of McCune-Albright syndrome. In earlier work, Atossa reported that Duchenne muscular dystrophy involves dysfunction in several biological systems, as detailed in findings released on the disease's complexity.